Minimal Residual Disease in Melanoma

Knowledge about diagnostic procedures in melanoma has in creased rapidly within the past few years. Single tumor cells have been identified in normal tissue such as sentinel lymph nodes, as well as in bone marrow, peripheral blood, and other bodily fluids and cells, by molecular technologies. The introduction of polymerase chain reaction-based methods can be regarded as a prototype of this dramatic development towards molecular approaches in new diagnostic procedures. This fact opens up the possibility of clinical use in patients and of influencing treatment strategies. Considerable discrepancies have been described, how ever, in the success rates of these new techniques for the detec tion of minimal residual disease in cancer patients. Despite fav orable results reported by different groups of investigators, it will take several years to define the clinical and pathophysiological relevance of new diagnostic procedures. The 1st International Symposium "Minimal Residual Disease in Melanoma: Biology, Detection and Clinical Relevance of Microme tastases", held in September 1999 in Homburg/Saar, Germany, fo cused on recent developments in this particular area of cancer re search. The purpose of the meeting was to stimulate discussion and exchange of new data and ideas by renowned international scientists. The aim of this volume is to summarize major topics of basic research and clinical investigations presented by invited experts in this fascinating but still. controversial field of melanoma re search.

Includes supplementary material: sn.pub/extras

Klappentext

This volume comprises the proceedings of the First International Symposium on Minimal Residual Disease in Melanoma, held in Homburg/Saar, Germany in September 1999. Containing contributions by 24 renowned experts, the book covers all aspects of diagnosis and treatment of micrometastatic disease in melanoma. The topics include: biology of micrometastases and advanced methods for detection; detection of residual melanoma cells in the peripheral blood and bone marrow; detection of minimal residual disease in sentinel nodes; early recognition and monitoring by serological markers; clinical relevance of micrometastasis detection; therapeutic strategies to deal with residual melanoma cells.

Zusammenfassung
Knowledge about diagnostic procedures in melanoma has in­ creased rapidly within the past few years. Single tumor cells have been identified in normal tissue such as sentinel lymph nodes, as well as in bone marrow, peripheral blood, and other bodily fluids and cells, by molecular technologies. The introduction of polymerase chain reaction-based methods can be regarded as a prototype of this dramatic development towards molecular approaches in new diagnostic procedures. This fact opens up the possibility of clinical use in patients and of influencing treatment strategies. Considerable discrepancies have been described, how­ ever, in the success rates of these new techniques for the detec­ tion of minimal residual disease in cancer patients. Despite fav­ orable results reported by different groups of investigators, it will take several years to define the clinical and pathophysiological relevance of new diagnostic procedures. The 1st International Symposium "Minimal Residual Disease in Melanoma: Biology, Detection and Clinical Relevance of Microme­ tastases", held in September 1999 in Homburg/Saar, Germany, fo­ cused on recent developments in this particular area of cancer re­ search. The purpose of the meeting was to stimulate discussion and exchange of new data and ideas by renowned international scientists. The aim of this volume is to summarize major topics of basic research and clinical investigations presented by invited experts in this fascinating but still. controversial field of melanoma re­ search.

Inhalt
I Biology of Micrometastases and Advances in Methods for Detection.- The Biology of Melanoma Micrometastases.- Disseminated Tumor Cells: Diagnosis, Prognostic Relevance, and Phenotyping.- Nested Quantitative Real Time PCR for Detection of Occult Tumor Cells.- Detection of Micrometastasis Through Tissue-Specific Gene Expression: Its Promise and Problems.- Immunobead-Based Detection and Characterization of Circulating Tumor Cells in Melanoma Patients.- Rapid Enrichment and Detection of Melanoma Cells from PBMC by a New Assay Combining Immunomagnetic Cell Sorting and Immunocytochemical Staining.- II. Detection of Residual Melanoma Cells in the Peripheral Blood and Bone Marrow.- Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Detection of Melanoma-Related Transcripts in the Peripheral Blood and Bone Marrow of Patients with Malignant Melanoma. What Have We Learned?.- The Clinical Utility of Multimarker RT-PCR in the Detection of Occult Metastasis in Patients with Melanoma.- Polymerase Chain Reaction in the Detection of Circulating Tumour Cells in Peripheral Blood of Melanoma Patients.- Facts and Pitfalls in the Detection of Tyrosinase mRNA in the Blood of Melanoma Patients by RT-PCR.- Morphologically Intact Melanoma Cells May Be Detected in Peripheral Blood of Melanoma Patients.- Prognosis of Metastatic Melanoma: No Correlation of Tyrosinase mRNA in Bone Marrow and Survival Time.- III. Detection of Minimal Residual Disease in Sentinel Nodes.- The Predictive Value of the Sentinel Lymph Node in Malignant Melanomas.- Detection of Micrometastasis in Sentinel Lymph Nodes of Patients with Primary Cutaneous Melanoma.- IV. Early Recognition and Monitoring by Serological Markers.- Monitoring Malignant Melanoma with the S-100B Tumour Marker.- Melanoma Inhibitory Activity (MIA), a Serological Marker of Malignant Melanoma.- Quantification of Melanoma-Associated Molecules in Plasma/Serum of Melanoma Patients.- V. Clinical Relevance of Micrometastases Detection.- Molecular Tools in the Detection of Micrometastatic Cancer Cells Technical Aspects and Clinical Relevance.- The Clinical Relevance of Molecular Staging for Melanoma.- Clinical Significance of PCR-Positive mRNA Markers in Peripheral Blood and Regional Nodes of Malignant Melanoma Patients.- Decrease in Circulating Tumor Cells as an Early Marker of Therapy Effectiveness.- VI. Therapeutic Strategies Against Residual Melanoma Cells.- Utility of Tests for Circulating Melanoma Cells in Identifying Patients Who Develop Recurrent Melanoma.- Active Specific Immunotherapy of Malignant Melanoma and Peptide Mimics of the Human High-Molecular-Weight Melanoma-Associated Antigen.- Autologous Dendritic Cells for Treatment of Advanced Cancer An Update.- A Novel Strategy in the Elimination of Disseminated Melanoma Cells: Chimeric Receptors Endow T Cells with Tumor Specificity.